

IMPORTANT PRESCRIBING INFORMATION

Switching patients from Liraglutide (Victoza®) to alternative products in Saudi Arabia due to Global Product Consolidation by 2026.

Direct Healthcare Professional Communication

Dear Healthcare professional,

This information is being disseminated in accordance with the national authority.

At Novo Nordisk Saudi Arabia we want to deliver medicines that will best serve the greatest number of patients globally. In order to better meet patient demand with a stable product supply, we are consolidating our portfolio. As part of the portfolio consolidation process Victoza® will be phased out in Saudi Arabia by the end of 2026. The phase out is not a consequence of any safety or quality related issues.

We acknowledge that this will be disruptive to people living with diabetes who rely on our treatments. As we strive not to leave any patients without alternative treatment options, either from Novo Nordisk or other companies, it is important to us that the transition to other device or treatment options is as smooth as possible for patients. We are therefore doing everything we can to liaise early with and support healthcare professionals, wholesalers, and patients in the transition to other treatments.

In relation to that, Novo Nordisk Saudi Arabia would like to inform you of the following:

Summary and background information

- Victoza® is a Glucagon-like peptide-1 (GLP-1) analogue, indicated for maintenance of blood glucose levels and help to reduce the risk of cardiovascular events in people with type 2 diabetes mellitus.
- Victoza® is indicated for the treatment of adults, adolescents and children aged 10 years and above with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise
 - As monotherapy.
 - In addition to other medicinal products for the treatment of diabetes.
- Victoza® is indicated to prevent Major Adverse Cardiovascular Events (MACE: cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in

adults with type 2 diabetes mellitus at high cardiovascular risk, as an adjunct to standard of care therapy

- Presentation: Victoza 6 mg/ml solution for injection in pre-filled pen (FlexPen®)
- If patients are not timely switched to an appropriate alternative treatment option, this could result in patients missing the required doses, which may lead to serious clinical consequences, specifically hyperglycemia that may eventually progress to diabetic ketoacidosis.
- Healthcare professionals (HCPs) are urged to ensure that patients using Victoza® are made aware of this and safely switched to alternative GLP-1 analogues or other alternatives at HCP's discretion and based on local routine clinical practices.

Mitigating actions

Due to the phase out, the mitigating actions outlined below should be considered:

- Transitioning between different types of GLP-1 analogues or to another brand or manufacturer of GLP-1 analogues to alternative GLP-1 analogues or other alternatives should be done in consultation with the physician and requires strict medical supervision.
- HCPs are requested to provide clear instructions of usage to the patient, if switched to alternative GLP-1 analogues or other alternatives.
- HCPs are requested to follow product SmPCs/labels for dosing recommendations while switching patients to alternative products.
- Patient should be fully informed about the reason for change in medication and the potential need for change in dose and additional glucose monitoring.
- Ensure that HCPs discuss potential dose adjustments and the need for continuous glucose monitoring during the transition period.
- HCPs are requested to remind their colleagues of these actions, particularly if they are known to be prescribers of the Victoza®.
- We are informing regulatory authorities, physicians, healthcare providers and patient organizations well in advance to help ensure patients transition safely to alternative options for continuity of care.

Call for reporting

Adverse events including medication errors relating to any Novo Nordisk products should be reported to:

National Pharmacovigilance Center (NPC) - Saudi Food and Drug Authority (SFDA)

SFDA call center: 19999

E-mail: npc.drug@sfd.gov.sa

Website: <http://ade.sfd.gov.sa/>

Novo Nordisk Saudi Arabia

E-mail: nngulfsafety@novonordisk.com

Website: <https://www.novonordisk.com.sa/>



Company contact point

Further information can be obtained by contacting nngulfsafety@novonordisk.com

Yours Sincerely

Shoug Alamer

Qualified Person for Pharmacovigilance

+966500686169 (mobile)

+966112728888 (direct)

Usga@Novonordisk.com

Novo Nordisk Saudi Arabia

Annexes

References

- 1- Victoza® Summary of Product Characteristics.